REQUEST A DEMO
Total
USD $0.00
Search more companies

Daiichi Sankyo Ilac Ticaret Ltd. Sti. (Turkiye)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Daiichi Sankyo Ilac Ticaret Limited Sirketi Profile Updated: May 07, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2021 Available in: English Download a sample report

daiichi-sankyo turkey Turkey is a global pharmaceutical company. The company focuses on developing medicinal solutions for cardiovascular diseases, diabetes, metabolism, and osteoporosis. daiichi-sankyo turkey claims to have a strong presence in Europe and is dedicated to developing new treatments for cancer patients and other high medical needs. The company also engages in global research and development activities and has a pharmaceutical portfolio for cardiovascular diseases. Additionally, daiichi-sankyo turkey is involved in social aid projects and clinical studies for antithrombotic agents.

Headquarters
F Blok Apartmani N:82 F-57 Unalan Mahallesi Libadiye Caddesi Emaar Square Sitesi Uskudar
Istanbul; Marmara; Postal Code: 34700

Contact Details: Purchase the Daiichi Sankyo Ilac Ticaret Ltd. Sti. report to view the information.

Website: http://www.daiichi-sankyo.com.tr

Basic Information
Total Employees:
Purchase the Daiichi Sankyo Ilac Ticaret Ltd. Sti. report to view the information.
Outstanding Shares:
Purchase the Daiichi Sankyo Ilac Ticaret Ltd. Sti. report to view the information.
Incorporation Date:
March 13, 2008
Key Executives
Purchase this report to view the information.
Company Manager
Company Performance
Financial values in the chart are available after Daiichi Sankyo Ilac Ticaret Ltd. Sti. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TRY. Absolute financial data is included in the purchased report.
Net sales revenue
106.46%
Total operating revenue
106.46%
Operating profit (EBIT)
-99.59%
Net Profit (Loss) for the Period
-99.59%
Total assets
96.9%
Total equity
92.31%
Operating Profit Margin (ROS)
-13.96%
Net Profit Margin
-13.96%
Return on Equity (ROE)
-21.6%
Quick Ratio
-0.14%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?